Improving the Nicotinic Pharmacophore with a Series of (Isoxazole)methylene-1-azacyclic Compounds: Synthesis, Structure−Activity Relationship, and Molecular Modeling
摘要:
A series of (isoxazole)methylene-1-azacyclic compounds was prepared. The compounds were tested for affinity to central nicotinic acetylcholine receptors (nAChRs) and central muscarinic receptors. The compounds covered a broad range of affinities for the nAChRs (IC50 = 0.32 to >1000 nM), with selectivities for the nAChRs over the muscarinic receptors in the range of 3-183. The high-affinity compound (Z)-26 (3-(4-methyl-5-isoxazolyl)methylene-1-azabicyclo-[2.2.2]octane, IC50 = 3.2 nM) having only one energy minimum was used as the reference structure in a computational study. This ligand has enabled definition of an important distance parameter, and the existence of this parameter was supported by showing that other potent nicotinic ligands (for example, nicotine and epibatidine) fit the model.
Improving the Nicotinic Pharmacophore with a Series of (Isoxazole)methylene-1-azacyclic Compounds: Synthesis, Structure−Activity Relationship, and Molecular Modeling
摘要:
A series of (isoxazole)methylene-1-azacyclic compounds was prepared. The compounds were tested for affinity to central nicotinic acetylcholine receptors (nAChRs) and central muscarinic receptors. The compounds covered a broad range of affinities for the nAChRs (IC50 = 0.32 to >1000 nM), with selectivities for the nAChRs over the muscarinic receptors in the range of 3-183. The high-affinity compound (Z)-26 (3-(4-methyl-5-isoxazolyl)methylene-1-azabicyclo-[2.2.2]octane, IC50 = 3.2 nM) having only one energy minimum was used as the reference structure in a computational study. This ligand has enabled definition of an important distance parameter, and the existence of this parameter was supported by showing that other potent nicotinic ligands (for example, nicotine and epibatidine) fit the model.
NOVEL SUBSTITUTED AZACYCLIC OR AZABICYCLIC COMPOUNDS
申请人:NOVO NORDISK A/S
公开号:EP0871627A1
公开(公告)日:1998-10-21
[EN] NOVEL SUBSTITUTED AZACYCLIC OR AZABICYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES AZACYCLIQUES OU AZABICYCLIQUES A SUBSTITUTION
申请人:NOVO NORDISK A/S
公开号:WO1997011073A1
公开(公告)日:1997-03-27
(EN) The present invention relates to therapeutically active heterocyclic compounds, to methods for their preparation and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system related to malfunctioning of the nicotinic cholinergic system.(FR) Cette invention a trait à des composés hétérocycliques à activité thérapeutique, à des procédés permettant leur préparation ainsi qu'à des compositions pharmaceutiques les contenant. Ces nouveaux composés se révèlent utiles dans le traitement de maladies du système nerveux central liées à un dysfonctionnement du système cholinergique nicotinique.
Improving the Nicotinic Pharmacophore with a Series of (Isoxazole)methylene-1-azacyclic Compounds: Synthesis, Structure−Activity Relationship, and Molecular Modeling
作者:Janne E. Tønder、John Bondo Hansen、Mikael Begtrup、Ingrid Pettersson、Karin Rimvall、Birgitte Christensen、Ulrich Ehrbar、Preben H. Olesen
DOI:10.1021/jm9910627
日期:1999.12.2
A series of (isoxazole)methylene-1-azacyclic compounds was prepared. The compounds were tested for affinity to central nicotinic acetylcholine receptors (nAChRs) and central muscarinic receptors. The compounds covered a broad range of affinities for the nAChRs (IC50 = 0.32 to >1000 nM), with selectivities for the nAChRs over the muscarinic receptors in the range of 3-183. The high-affinity compound (Z)-26 (3-(4-methyl-5-isoxazolyl)methylene-1-azabicyclo-[2.2.2]octane, IC50 = 3.2 nM) having only one energy minimum was used as the reference structure in a computational study. This ligand has enabled definition of an important distance parameter, and the existence of this parameter was supported by showing that other potent nicotinic ligands (for example, nicotine and epibatidine) fit the model.